BioProcessing Journal · 2003 · 18 citations · 14 references
EngineeringBioengineeringBiotechnologyBioreactor DesignCell TherapyTissue EngineeringCell CultureCell Culture TechnologyCell ManufacturingCell ProcessingCell Therapy ManufacturingCellular ManufacturingAutologous Car T-cell TherapyAutologous Cell ManufacturingBioreactor Process DesignCell Source Manufacturing FeasibilityImmune Cell ManufacturingManufacturing Of Therapeutic CellsT Cell ProcessingT-cell Manufacturing
Xcyte Therapies has recently introduced a bioreactor-based process for the GMP manufacture of autologous activated T cells, Xcellerated T Cells™, for clinical trials. Using a single customized disposable 20-L Cellbag™ with a working volume of 10 L on a customized Wave Bioreactor platform (Wave Biotech, Bridgewater, NJ), the Xcellerate™ III Process has supplanted the 60-L static Xcellerate II Process that used 60 bags cultured in a standard incubator. Compared to the Xcellerate II™ Process, the Xcellerate III Process significantly reduces the overall labor, the number of culture containers, bag spikes, and sterile connections required, as well as reducing the process volume and the cost of goods, while more than quadrupling the final cell density and doubling the facility capacity. These process improvements are achieved without compromising final product composition or quality.
14
Jack Gorski, Maryam Yassai, Xiaoyan Zhu et al. · The Journal of Immunology · 1995 · 385 citations · Full text
Jessica A. Gorski, Maryam Yassai, Xiaochun Zhu et al. · The Journal of Immunology · 1994 · 352 citations · Full text